Hormone Therapy for Hormonal Imbalance — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hormone therapy (HT), also known as hormone replacement therapy (HRT), encompasses the medical administration of hormones — or hormone-modifying agents — to correct clinically documented hormonal deficiencies, imbalances, or excesses that cause symptoms and increase disease risk. Hormones are chemical messengers produced by endocrine glands (pituitary, thyroid, adrenal, ovaries, testes) that regulate virtually every physiological system including metabolism, reproduction, bone density, cardiovascular health, mood, and cognitive function.

The most common clinical applications of hormone therapy include: menopausal hormone therapy (MHT) for oestrogen and progesterone replacement in perimenopausal and postmenopausal women; testosterone replacement therapy (TRT) for male hypogonadism; thyroid hormone replacement (levothyroxine) for hypothyroidism; gender-affirming hormone therapy (GAHT) for transgender and non-binary individuals; and corticosteroid replacement for adrenal insufficiency. Less commonly, growth hormone therapy for documented growth hormone deficiency, and hormonal contraception which suppresses ovulatory hormones.

Hormone therapy is prescribed and monitored by endocrinologists, gynaecologists, urologists, or general practitioners with expertise in hormonal conditions. Treatment requires baseline hormonal blood testing, risk stratification, and individualised hormone dosing through the appropriate delivery route. All hormone therapy requires regular monitoring for efficacy, safety, and dose adjustment throughout treatment.

Hormone therapy addresses a broad spectrum of endocrine conditions. Menopausal hormone therapy (MHT) treats vasomotor symptoms (hot flushes, night sweats), genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary urgency), sleep disturbance, mood dysregulation, and prevents osteoporosis and — in women starting before age 60 or within 10 years of menopause — provides cardiovascular protection according to the 2022 Menopause Society position statement. Testosterone replacement therapy corrects hypogonadism symptoms including fatigue, reduced libido, erectile dysfunction, mood disturbance, reduced muscle mass, and osteopenia.

Gender-affirming hormone therapy for transgender women (feminising HT: oestradiol plus anti-androgens) and transgender men (masculinising HT: testosterone) achieves gender-congruent secondary sexual characteristics. Thyroid hormone replacement with levothyroxine corrects hypothyroidism — addressing fatigue, weight gain, cold intolerance, and bradycardia. Adrenal insufficiency (primary or secondary) is treated with glucocorticoid replacement (hydrocortisone or prednisolone) plus mineralocorticoid replacement (fludrocortisone for primary adrenal insufficiency). Growth hormone deficiency in adults is treated with daily subcutaneous somatropin injections.

Candidacy for hormone therapy is determined by a confirmed hormonal deficiency or imbalance on laboratory testing, clinically significant symptoms attributable to the hormonal state, and a benefit-risk assessment weighing the expected therapeutic gain against the patient's individual risk profile. For menopausal HT, women who are symptomatic with no contraindications — including those without a history of hormone-sensitive malignancy, venous thromboembolism, or undiagnosed vaginal bleeding — are appropriate candidates. Women under 60 or within 10 years of menopause who are symptomatic have a favourable benefit-risk profile according to current international guidelines.

Contraindications vary by the specific hormone and indication. For oestrogen-containing menopausal HT: current or history of breast cancer (relative/absolute contraindication), active venous thromboembolism, active liver disease, and undiagnosed abnormal uterine bleeding. For testosterone therapy: prostate cancer (absolute), breast cancer (absolute), polycythaemia, severe heart failure, and untreated severe sleep apnoea. For gender-affirming HT, comprehensive psychological assessment and diagnosis of gender dysphoria/gender incongruence as per WPATH Standards of Care Version 8 is required.

Hormone therapy is delivered through multiple routes, each with different pharmacokinetic profiles, risk implications, and patient preferences. For menopausal HT: oral oestradiol tablets, transdermal oestradiol patches or gel (preferred route due to bypassing first-pass hepatic metabolism, reducing VTE and stroke risk compared to oral), topical oestradiol spray, and subcutaneous pellet implants. Progesterone or progestogen is added for endometrial protection in women with an intact uterus — micronised progesterone (Utrogestan) is favoured due to its neutral cardiovascular and breast cancer risk profile compared to synthetic progestogens.

For testosterone replacement: intramuscular or subcutaneous testosterone injections (cypionate, enanthate), transdermal testosterone gel or patches, and subcutaneous pellets. Gel formulations maintain more stable serum levels compared to fortnightly injections. For gender-affirming HT: feminising regimens typically use transdermal oestradiol plus an anti-androgen (spironolactone, bicalutamide, or GnRH analogue). Masculinising regimens use testosterone injections or gel. Thyroid replacement uses oral levothyroxine (L-T4), typically morning on an empty stomach, titrated to maintain TSH within the target range (0.5–2.5 mIU/L).

Clinical selection of the most appropriate treatment modality requires integration of the best available evidence with individual patient factors including comorbidities, prior treatment response, patient values, and resource availability. Multidisciplinary team discussion ensures that treatment decisions reflect comprehensive clinical expertise across relevant specialties. Patient education and shared decision-making are fundamental components of high-quality care in this area, enabling patients to make informed choices aligned with their healthcare goals.

Menopausal hormone therapy is the most effective treatment for vasomotor symptoms (hot flushes, night sweats), reducing frequency by 75–80% compared to placebo. It significantly improves sleep quality, mood, sexual function, and genitourinary symptoms, and prevents bone loss reducing vertebral fracture risk by 30–35%. Started in women aged under 60 or within 10 years of menopause, MHT is associated with reduced cardiovascular mortality and improved overall survival in observational data, reversing earlier concerns raised by the 2002 WHI trial (which enrolled predominantly older, higher-risk women).

Testosterone replacement in hypogonadal men substantially improves energy, libido, erectile function, mood, bone density, and muscle mass. Gender-affirming HT produces valued feminising or masculinising physical changes that significantly improve gender dysphoria, mental health outcomes, and quality of life — with studies showing substantial reductions in suicidality and depression following GAHT. Thyroid hormone replacement effectively resolves all symptoms of hypothyroidism with appropriate dosing.

The risks of hormone therapy are highly dependent on the specific hormone, route of administration, dose, duration, patient age, and individual health profile. For menopausal HT: oral oestrogen increases VTE risk approximately 2-fold (transdermal oestrogen does not increase VTE risk). Combined oestrogen-progestogen MHT increases breast cancer risk with long-term use (approximately 1 extra case per 1,000 women per year of use after 5 years) — oestrogen-only MHT in hysterectomised women does not increase breast cancer risk at 7 years. Bioidentical micronised progesterone appears to carry less breast cancer risk than synthetic progestogens.

For testosterone therapy: polycythaemia (raised red blood cell count, managed by dose reduction or venesection), acne, sleep apnoea exacerbation, and — of ongoing study — potential cardiovascular risk in older men. For gender-affirming HT: anti-androgen spironolactone can cause hyperkalaemia and hypotension. Oestrogen in transgender women carries a dose-dependent VTE risk (mitigated by transdermal route). Testosterone in transgender men causes irreversible virilisation effects (voice deepening, clitoral growth). All hormone therapies require regular laboratory monitoring.

Hormone therapy requires ongoing medical supervision throughout its duration rather than a single course of treatment. Initial follow-up is typically at 3 months after initiation to assess symptom response, check hormone levels (TSH for thyroid; total and free testosterone, haematocrit for TRT; oestradiol, FSH, LH for MHT), and adjust dosing accordingly. Annual review thereafter covers monitoring of hormone levels, relevant safety markers (breast screening for women on MHT, PSA and haematocrit for men on TRT, cardiovascular risk factors for all), and reassessment of ongoing benefit and risk.

For menopausal HT, the duration of treatment is individualised — current guidelines support continuing MHT as long as the benefit outweighs the risk, which for most symptomatic women means 5–10 years or longer. There is no mandatory maximum duration stipulated in current guidelines from NICE (UK), the Menopause Society (US), or IMS (International Menopause Society). For hypothyroidism, levothyroxine replacement is typically lifelong.

Hormone therapy costs vary by the type of hormone, brand (branded vs. generic), delivery route, and country-specific healthcare funding. In the United States without insurance, monthly transdermal oestradiol gel costs USD 30–80, oral progesterone USD 20–60, and testosterone gel USD 40–120 per month — with annual endocrinologist monitoring visits adding USD 500–2,000 per year. In the United Kingdom, MHT is available on NHS prescription at standard prescription charges; private prescriptions cost GBP 20–80 per month.

In India, generic hormone therapy formulations (levothyroxine, oestradiol, testosterone) are extremely affordable — often costing USD 2–15 per month. Private endocrinology consultations in India cost USD 20–60 per visit at top hospitals. Patients requiring specialist hormonal assessment and treatment who cannot access affordable care domestically can attend comprehensive endocrinology assessments at leading private hospitals in India (AIIMS Delhi, Apollo, Fortis, Manipal) for USD 50–200 total for assessment and 3-month treatment initiation — saving 70–90% compared to US out-of-pocket costs.

For menopausal symptoms, non-hormonal alternatives include: SSRIs and SNRIs (paroxetine, venlafaxine, desvenlafaxine) — particularly appropriate for women with a history of hormone-sensitive breast cancer — which reduce hot flush frequency by 50–60% in RCTs; gabapentin or pregabalin for vasomotor and sleep symptoms; and fezolinetant (Veoza) — a recently FDA-approved neurokinin 3 receptor antagonist specifically for menopausal hot flushes without hormonal mechanism. Cognitive-behavioural therapy (CBT) for menopausal symptoms has evidence for improving sleep, mood, and perceived hot flush impact.

For male hypogonadism in men with obesity, weight loss and exercise can meaningfully increase endogenous testosterone — the most sustainable first-line intervention before pharmacological TRT in appropriate patients. For thyroid disorders, natural desiccated thyroid preparations (containing both T4 and T3) are used by some patients who prefer them over synthetic levothyroxine, though current guidelines note equivalent evidence of efficacy. Complementary approaches (phytoestrogens, black cohosh) have weak and inconsistent evidence for menopausal symptom relief and are not recommended as replacements for evidence-based HT in severely symptomatic women.